<DOC>
	<DOCNO>NCT02940691</DOCNO>
	<brief_summary>This study phase IV , open-label , single arm , multicentre study whose aim ass whether interferon-free ribavirin-free Direct Acting Antiviral ( DAA ) Hepatitis C Virus ( HCV ) therapy grazoprevir/elbasvir , feasible treatment People inject drug ( PWID ) recent inject drug use chronic HCV genotype 1 4 infection .</brief_summary>
	<brief_title>Scale-up Treatment Hepatitis C Infection Among People Who Inject Drugs</brief_title>
	<detailed_description>A prospective , observational cohort design use enrol patient attend tertiary , drug alcohol primary health care service Sydney , Australia . The study consist treatment phase ( 12 week ) follow-up phase ( 3 year ) participant follow every 3 month first year every 6 month year 2-3 evaluate treatment response reinfection . The effectiveness treatment assess look proportion patient undetectable HCV RNA 12 week post end treatment ( SVR12 ) follow therapy grazoprevir/elbasvir evaluate demographic clinical predictor non-response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Participants voluntarily sign informed consent form . Be ≥18 year age day sign informed consent form . Have HCV infection document detectable HCV RNA . Have HCV genotype 1 4 infection . Recent inject drug use ( previous 6 month ) . HIV1 infected subject enrol study must meet following criterion : Have HIV infection document licensed rapid HIV test HIV enzyme chemiluminescence immunoassay ( E/CIA ) test kit time prior study entry ( Baseline ) confirm licensed Western blot second antibody test method initial rapid HIV and/or E/CIA , HIV1 p24 antigen , plasma HIV1 RNA viral load Be naive treatment antiretroviral therapy ( ART ) ( plan initiate ART treatment participate study least Followup Week 4 OR HIV Antiretroviral Therapy ( ART ) least 4 week prior study entry use ART regimen allowable intend DAA regimen determine current PI Liverpool drug interaction website ( http : //www.hivdruginteractions.org/ ) current prescribe guideline grazoprevir/elbasvir . Negative pregnancy test screen baseline ( female childbearing potential ) . All fertile male female must use effective contraception treatment 14 day treatment end . Is take plan take prohibit medication per DAA Product Information herbal supplement , include limited St. John 's Wort ( Hypericum perforatum ) within 2 week Baseline . Is currently use intend use barbiturate . Is female pregnant breastfeeding , expect conceive donate egg Baseline continue throughout treatment , last dose study medication ( per regimen requirement ) , longer dictate local regulation . Has condition prestudy laboratory abnormality , ECG abnormality history illness , , opinion investigator , might confound result study pose additional risk administer study drug subject . Had lifethreatening SAE screen period . Has exclusionary laboratory value list : Haemoglobin &lt; 9.5 g/dL male females Platelets &lt; 50 x 103 /µL Serum albumin &lt; 3.0 g/dL Patients Child PughB C decompensated cirrhosis Previous HCV treatmentexperience . Ongoing severe psychiatric disease judge treat physician . Frequent inject drug use judge treat physician compromise treatment safety . Inability unwillingness provide inform consent abide requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>